You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back

Retention in focal epilepsy

Keppra achieved significantly better retention than CBZ in patients with focal epilepsy as a monotherapy1

Time to withdrawal of allocated treatment1

A Cochrane review of monotherapy RCTs in adults or children with focal seizures or generalised tonic-clonic seizures (with or without other generalised seizure types) to assess time to withdrawal of allocated treatment (n=11,978). The above graph indicates direct and indirect evidence (network meta-analysis) of 8 AEDs as compared with CBZ in patients with focal epilepsy.1

Figure reproduced with permission from Nevitt SJ, et al. Cochrane Database Syst Rev 2017, Issue 12. Art. No.: CD011412. © Copyright 2017 The Cochrane Collaboration. Reprinted with permission from John Wiley and Sons.

Safety information: Headache or migraine was the most commonly reported adverse event of lamotrigine, levetiracetam and zonisamide.1


more about Keppra more about Keppra

Read more about Keppra


AED: anti-epileptic drug; CBZ: carbamazepine; CI: confidence interval; RCT: randomised controlled trial; SD: study design.


  1. Nevitt SJ, et al. Cochrane Database Syst Rev 2017;12:CD01141.

GSK shall not be liable for any damages, claims, liabilities, costs or obligations arising from the use or misuse of information provided herein. 
For safety information on GSK products or to report an Adverse Event, please contact the toll free line 
0800 CALL GSK (0800 2255 475) or email 
Full prescribing information is available on request on
Please note that it may take up to 10 days to process your request. If you need further assistance contact 
GSK House, 1 Industrial Avenue llupeju, Lagos or via email at
GlaxoSmithKline Pharmaceutical Nigeria Ltd, 1 Industrial Avenue, llupeju, Lagos 234-1-271 1000 
©2020 GSK group of companies or its licensor 
Trade marks are owned by or licensed to the GSK group of companies

Keppra is a registered trademark of the GlaxoSmithKline group of companies

PM-NG-LVT-WCNT-200004 Date of preparation: November 2020.